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Background: Currently, only two drugs are recommended for treatment of
infection with Trypanosoma cruzi, the etiologic agent of Chagas' disease. These
compounds kill the trypomastigote forms of the parasite circulating in the
bloodstream, but are relatively ineffective against the intracellular stage of the
parasite life cycle. Neither drug is approved by the FDA for use in the US. The
hypoxanthine phosphoribosyltransferase (HPRT) from T. cruzi is a possible new
target for antiparasite chemotherapy. The crystal structure of the HPRT in a
conformation approximating the transition state reveals a closed active site that
provides a well-de¢ned target for computational structure-based drug discovery.
Results: A £exible ligand docking program incorporating a desolvation correction
was used to screen the Available Chemicals Directory for inhibitors targeted to
the closed conformation of the trypanosomal HPRT. Of 22 potential inhibitors
identi¢ed, acquired and tested, 16 yielded Ki's between 0.5 and 17 WM versus the
substrate phosphoribosylpyrophosphate. Surprisingly, three of eight compounds
tested were effective in inhibiting the growth of parasites in infected mammalian
cells.
Conclusions: This structure-based docking method provided a remarkably
ef¢cient path for the identi¢cation of inhibitors targeting the closed conformation of
the trypanosomal HPRT. The inhibition constants of the lead inhibitors identi¢ed
are unusually favorable, and the trypanostatic activity of three of the compounds
in cell culture suggests that they may provide useful starting points for drug
design for the treatment of Chagas' disease.
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Introduction
Trypanosoma cruzi is the etiologic agent of Chagas’ disease,
which affects 16^18 million people in Latin America and
more than 300 000 US immigrants [1^3]. Acute infection,
often occurring in childhood, can lead to death by heart
failure or meningoencephalitis, and chronic infection can
lead to heart failure or the mega-syndromes affecting the
esophagus or colon [1]. Currently only two drugs are rec-
ommended for treatment of Chagas’ disease, Nifurtimox
and Benznidazole [4]. These compounds kill the trypomas-
tigote forms of the parasite circulating in the bloodstream
and are effective in reducing many symptoms during the
acute phase of infection, however, they do not completely
eliminate the parasites and are relatively ineffective against
the intracellular stage of the parasite life cycle. Treatment
with either drug is complicated by serious toxic side ef-
fects, thus, new drugs for the treatment of Chagas’ disease
are urgently needed.
To identify potential target enzymes for structure-based
inhibitor design, differences in host and parasite metabo-
lism may be identi¢ed and exploited. One such difference
exists between humans and protozoan parasites in the
pathways for purine nucleotide biosynthesis. Unlike mam-
mals, protozoan parasites do not possess the enzymes re-
quired for the de novo synthesis of purine nucleotides [5,6]
and rely entirely on salvage pathways for the purine nu-
cleotides needed in cellular metabolism [6]. In T. cruzi, the
hypoxanthine phosphoribosyltransferase (HPRT; EC
2.4.2.8) is responsible for salvage of both hypoxanthine
(Hx) and guanine bases from host nutrient pools for use
in purine nucleotide synthesis [7,8]. This enzyme has been
proposed as a target for antiparasite chemotherapy [5,9^
11].
The HPRT catalyzes the transfer of a phosphoribosyl
group from phosphoribosylpyrophosphate (PRPP) to a pu-
CHBIOL 44 18-12-00 Cyaan Magenta Geel Zwart
Research Paper 957
rine base (Hx or guanine) to form a purine ribonucleotide,
inosine monophosphate (IMP) or guanosine monophos-
phate (GMP), respectively (Figure 1). A number of apo,
ion and product-bound HPRT crystal structures show dis-
order of a long active site loop (loop II, which contains
invariant residues Ser81^Tyr82) [12^16], suggesting that
the active site chemistry [17] is sequestered from bulk
solvent by the formation of a ‘closed’ conformation of the
£exible loop II not seen in these structures. The ¢rst
structure with a closed and catalytically relevant conforma-
tion of the long £exible loop was that of the trypanosomal
enzyme in ternary complex with the substrate PRPP and a
substrate (Hx) analog [18]. In one subunit of the dimer,
loop II is in a well-ordered closed conformation approxi-
mating that expected near the transition state. In the
closed active site, the ternary substrate complex is almost
completely protected from bulk solvent [18].
We reasoned that the closed active site would provide a
favorable target for structure-based drug discovery. A com-
mon problem in docking ligands to proteins is that the
target binding site is a fairly open surface, which effec-
tively restricts the useful three-dimensional (3D) function-
ality of the ligand to interactions with a surface that, in the
worst case, is little more than two-dimensional. An open
active site further provides no restrictions on functionality
extending into solvent, so that the computational search
becomes less ef¢cient due to many possible ‘hits’ that in-
clude large solvent exposed groups irrelevant to the pre-
dicted binding interactions. In the HPRT, closure of loop
II completely de¢nes a 3D space unique to the active site
of the enzyme that can be exploited for structure-based
drug design. The closed active site structure provides
both a relatively restrictive target, which should result in
more ef¢cient identi¢cation of ‘hits’, and a well-de¢ned
3D target volume surface that should maximize the infor-
mation available to increase af¢nity and speci¢city of lead
compounds.
Recent developments in molecular docking have ad-
dressed limitations caused by failure to allow £exibility of
the interacting structures and by omission of a desolvation
energy term in evaluating the energetics of binding to the
target. The problem in the ¢rst case is that consideration of
all possible conformations of both ligand and target can
become computationally intractable. A protocol that sim-
pli¢es and accelerates the evaluation of multiple ligand
conformations has been implemented [19] and was used
in this work. In this method, the conformational space of
the database is simpli¢ed by expanding only over rotamers,
and molecular docking is carried out in two stages, the ¢rst
of which considers only the largest rigid fragment of each
molecule. The result is a rapid, simple protocol that never-
theless allows evaluation of millions of conformations in
the docking experiment. The problem in the second case
is that of ¢nding a reasonable approximation to account for
the energetics of desolvation of both the active site and the
ligand that accompanies binding. Such an expression has
been identi¢ed [20] and is implemented in the program
used here. Because it posits complete desolvation of the
ligand on binding, this simple desolvation correction is
particularly relevant to the case under consideration, in
that closure of the active site of the HPRT should result
in sequestration of the ligand from bulk solvent.
The modi¢ed version of the program DOCK [19^22] was
used to screen an expanded database of over 34 million
chemical structures for steric ¢t and predicted binding in-
teraction with the closed active site structure of the HPRT
from T. cruzi. A number of the computational hits were
characterized biochemically and the majority of these com-
pounds were found to inhibit the activity of the trypano-
somal HPRT. In most cases, the kinetics of inhibition were
consistent with the predicted binding mode. Of the mole-
cules that inhibited the activity of the puri¢ed enzyme,
three inhibited growth of trypanosomes in mammalian
cell culture.
Figure 1. The reaction catalyzed by
HPRT. HPRT catalyzes the reversible
addition of 6-oxo-purines to the C1P
position of the ribose of PRPP. The
reaction follows ordered bi^bi kinetics such
that PRPP binds ¢rst, followed by the
purine base and the product
pyrophosphate is released before the
product nucleotide [15,26,27]. There is
evidence to support both SN1 and SN2
type chemistries [18,50,51].
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Results
The closed active site target
The closed conformation of the T. cruzi HPRT encom-
passes an active site that spans approximately 11U11U7
Aî and encloses a volume of approximately 610 Aî 3. In the
crystal structure this space is entirely accounted for by
well-ordered ligand atoms; these include the PRPP sub-
strate, a purine substrate analog, two magnesium ions and a
total of 14 water molecules (¢ve of which are in the ¢rst
coordination spheres of the two magnesium ions) [18]. Five
Figure 2. The active site of the HPRT in a closed conformation. (A) A cutaway view of the molecular surface of the active site of the
closed conformation of the T. cruzi HPRT illustrating the position of the bound PRPP [18]. The view is through the £exible loop II, and a
number of the atoms of that loop are cut away. The loops I and III at each side of the active site form hydrogen bonding interactions with
the phosphate groups that position the PRPP, complexed with two magnesium ions, in a rigid conformation spanning the binding pocket.
Deeper inside the pocket (indicated by the arrow) is the purine binding site that is formed by a cluster of hydrophobic side chains. The
purine is buried in this view. Tyrosine 82 of loop II, center, is invariant. (B) A stereo view of the surface de¢ned by the closed active site
(dotted) in the context of an K carbon trace of the closed active site monomer. The orientation is rotated approximately 90³ from that
above. The surface is completely enclosed within the protein by the active site loops I^IV, by part of the second monomer of the dimer
(indicated on the left), and by side chains which pack over the active site at the top right (not shown). The volume of the space enclosed
by the surface is V610 Aî 3; the area of the surface is V548 Aî 2. This surface was the target for the DOCK screening described here.
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segments of the protein polypeptide backbone enclose the
region: residues 50^53 (loop I), 79^85 (loop II), 111^120
(loop III), 163^165 and 169^173 (loop IV) (Figure 2A).
The interior of the closed active site is almost entirely
inaccessible to bulk solvent (Figure 2B), with the excep-
tion of two small ‘holes’ at opposite ends of the active site
that expose a total of approximately 22 Aî 2, or V4% of the
surface area of the ligand ensemble, to the solvent. The
purine binding pocket is largely hydrophobic and is cre-
ated by four well-conserved side chains: Phe164 forms a Z^
Z stacking interaction above the purine base, and Ile113
(loop III), Val165 and Leu170 (loop IV) sandwich it from
behind and below. Neighboring main chain atoms interact
with purine ring heteroatoms. The bound PRPP spans the
binding pocket below the purine, with its 1P-pyrophos-
phate and 5P-phosphate groups interacting with residues
of loop I and loop III, respectively, through backbone
amide hydrogen bonds that stabilize the charged phos-
phate groups (Figure 2A). Two magnesium ions (termed
M1 and M2) coordinate oxygen atoms of the PRPP pyro-
phosphate group. One magnesium (M1) has no direct in-
teraction with the protein, while the other (M2) is coordi-
nated by an invariant aspartate (Asp171) carboxylate
oxygen. Thus, within the active site, there are different
binding pockets characterized by distinct hydrophobic, hy-
drogen bonding and charged interactions.
DOCK screening calculations
The active site was prepared for DOCK screening by re-
moving all 48 ligand atoms, including all ordered water
molecules. The site shape was then described in terms
of 55 DOCK spheres [23]. Although both will be addressed
in future studies (see below), we did not de¢ne the shape
of the site in terms of the ligand atomic positions [24], nor
did we consider a number of ‘structural’ water molecules
[25] observed in both the open and closed active sites of
the T. cruzi ternary complex structure, as well as in a num-
ber of other HPRT structures with various ligands bound.
The DOCK scoring grids were calculated over a 3D box
that extended well beyond the enclosed active site in each
dimension, in order to properly handle ‘leakage’ through
the two small openings in the closed site. The scoring grids
were calculated using the standard protocols for evaluation
of van der Waals and electrostatic potential energies [22].
A conformationally expanded database of well over 34 mil-
lion chemical structures [19] was then screened to assess
potential ¢t and force ¢eld interactions with the closed
active site (see Materials and Methods). The energy scores
included a correction for ligand desolvation [20]. The top
500 compounds from the database search were considered
for visual evaluation using computer graphics. The DOCK
energy scores ranged from a minimum of 335.6 kcal/mol
for the ¢rst to 323.7 kcal/mol for the 500th compound and
followed a somewhat hyperbolic distribution characteristic
of DOCK scoring results. Over this range the relative en-
ergy scores have little meaning, and it is conventional to
consider any of the top 500 compounds as candidates for
further characterization [25]. A number of compounds were
visually inspected for the plausibility of their predicted
binding mode and for their likely solubility in aqueous
media, and a subset of 22 compounds that minimized
chemical redundancy was selected for initial kinetic char-
acterization. The lowest scoring compound tested occurred
third in the scoring list (score 330.9), and the highest
occurred 389th (score 325.4); both proved to be low mi-
cro-molar inhibitors of the trypanosomal enzyme.
Predicted binding modes
We focus our discussion on four of the compounds identi-
¢ed in this study (Figure 3); their interactions can be taken
as representative of the interactions of the other com-
pounds identi¢ed in the DOCK screen. The predicted
binding modes of the four compounds, which we identify
as 1, 2, 3 and 4, are shown in Figure 4. Each occupies from
300^370 Aî 3 of the 610 Aî 3 available volume of the HPRT
binding pocket, generally within the broad central region
of the site (see Figure 4). In the predicted binding orien-
tations they interact with the pyrophosphate binding loop
I, and each makes van der Waals interactions with Tyr82 of
the closed £exible loop II. Both 3 and 4 present an aro-
matic ring to the hydrophobic purine binding pocket of the
active site, wedged between, and forming van der Waals
interactions with, residues Phe164 and Ile113. Phe164 is
Figure 3. The four inhibitory compounds discussed in the text.
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Figure 4. Predicted binding modes of four
inhibitors identi¢ed by DOCK. Stereo
images of the predicted binding modes of
the four lead compounds (see text). The
target DOCK surface is shown (dotted).
The active site loops (I^IV) are indicated;
side chains are drawn only for those
residues that directly contact the active site
ligand cluster. (A) Compound 1,
(B) compound 2, (C) compound 3,
(D) compound 4. The orientation is similar
to that in Fig. 2B.
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known to be £exible, so that a Z^Z stacking interaction
could easily occur. A £uorine atom of compound 3 (Figure
4C) is 2.9 Aî from loop IV mainchain atoms in the purine
binding pocket, and two chlorine atoms of the phenyl ring
bound in loop III are predicted in a position that could
contribute to van der Waals interactions as well. For com-
pound 4 (Figure 4D), an NO2 group is 2.8 Aî from the polar
environment of the Asp171 carboxylate. Compound 2 (Fig-
ure 3B) lacks an interaction with loop III and projects a
smaller group that contains some polar atoms into the pu-
rine binding pocket. Finally, compound 1 (Figure 4A) is
not predicted to bind extensively in either the purine
binding pocket or loop III. Instead, this compound inter-
acts primarily with loop I and occupies metal site M1, such
that at least ¢ve atoms are within hydrogen bond distance
to the sidechain of Asp171 and to mainchain atoms of
Ile135 and the closed £exible loop II.
The contact that each of the compounds makes with Tyr82
can occur only in the closed conformation of the HPRT
active site, and we believe it is signi¢cant that each of the
compounds identi¢ed here exhibits some packing interac-
tion with the closed £exible loop II. This is what distin-
guishes the result of the closed active site search from a
search of the open active site. A DOCK search targeting
the structure of the open monomer of the T. cruzi
HPRT[18] has been carried out as well; the best force ¢eld
score in that search was 324.6 kcal/mol, and all but that
one score was worse than any compound scores reported in
the closed active site search. A comparison of the predicted
binding modes of the top 500 ‘hits’ reveals that those tar-
geted to the open active site cluster against the back wall
of the active site, essentially the only surface de¢ned in
the target structure, while for the closed active site the
distribution more fully explores the available space of the
target volume, in particular, the space between loop I and
the closed loop II that is predicted to contribute substan-
tially to the binding interactions.
The compounds we have identi¢ed appear to complement
the closed binding cavity well, although only a fraction of
the 548 Aî 2 of surface area available in the binding pocket
is predicted to contribute to the van der Waals interaction
energy with the ligands (which have surface areas of 279^
348 Aî 2). Those parts of the active site cavity not ¢lled by
the bound ligand may accommodate solvent molecules,
Table 1
Inhibition of the forward reaction of the HPRT from T. cruzi.
MDL-ACDa Text reference Variable PRPP Variable Hx
MFCD# Ki (WM) typeb Kci;app (WM) type
1159 1 2.2 C 6.8 N-C
5062 6.2 C 4.9 N-C
22291 9.0 C 6.0 N-C
32937 2.8 C 10.6 C
32980 2 0.5 C 7.0 N-C
37501 3.3 N-C 21.8 N-C
93980 1.6 C 2.1 N-C
112201 7.9 C 4.4 C
124181 2.1 C 3.0 N-C
139585 16.6 N-C 15.7 N-C
139586 5.9 C 5.6 C
141430 3 11.8 U-C 10.6 C
156385 4 2.0 C 2.7 N-C
170659 4.8 C 15.2 C
171313 4.4 C 33.9 N-C
189063 9.4 C 29.7 N-C
Compounds in italics were tested for activity against trypanosomes in culture; those shown in bold italics inhibit trypanosome growth.
aMDL-ACD (the Available Chemicals Directory from MDL Information Systems) The full chemical name for each compound identi¢ed here
by its MFCD # is given in Materials and Methods.
bC (competitive), N-C (non-competitive), U-C (uncompetitive).
cMeasurements against variable Hx yield apparent inhibition constants (Ki;app)
Figure 5. Inhibition kinetics. Lineweaver^Burke plots of initial velocity for different concentrations of each of the lead compounds (see text).
The concentrations of inhibitor used were 0 WM (b), 0.625, 1.25, 2.5, 5 and 10 WM. In the plots labeled `PRPP' (left), PRPP was the varied
substrate, and in the plots labeled `Hx' (right), Hx was the varied substrate. Given a sequential bi^bi reaction model, the pattern of
inhibition of a compound that binds the empty active site should be competitive against the ¢rst substrate to bind (PRPP), and not
competitive against the second substrate to bind (Hx) [28]. This is seen for compounds 1, 2 and 4. Compound 3 is uncompetitive with
respect to PRPP. The insets show replots of the slopes for the three PRPP inhibition experiments that showed competitive behavior; these
yield the derived inhibition constants.
C
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and the predicted binding modes for a number of the
compounds would allow several of the crystallographically
observed water molecules to remain. Our inhibition ki-
netics data (below) are, in most cases, consistent with the
computational binding predictions, however, a real under-
standing of the relation between the predicted binding
modes and the actual binding modes awaits determination
of the structures of each of the complexes.
Kinetic studies
Twenty-two compounds identi¢ed in the DOCK screen
were acquired for biochemical characterization. Activity
against the forward reaction of the HPRT was assayed us-
ing a continuous spectrophotometric assay [26]. In initial
studies, 16 of the 22 compounds yielded IC50 values below
20 WM (data not shown); the inhibition activity of each of
these compounds was then fully characterized (Figure 5
and Table 1). Thirteen of the 16 exhibited competitive
inhibition kinetics against PRPP as the varied substrate,
yielding inhibition constants (Kis) between 500 nM and
10 WM. The patterns of inhibition with Hx as the varied
substrate were also determined for each of the 16 com-
pounds (Table 1). Previous product inhibition [26,27], li-
gand binding, pre-steady state kinetics and isotope ex-
change [15] studies have demonstrated that the reaction
mechanisms of the schistosomal, human and Tritrichomonas
foetus HPRTs exhibit ordered bi^bi kinetics [28]. Given
this framework we can ask whether the mode of inhibition
observed in kinetic studies is consistent with the binding
mode predicted in our computational screen. Indeed, the
pattern of competitive and non-competitive inhibition
against PRPP and Hx, respectively, that is seen with the
majority of the compounds tested is consistent with a bind-
ing mode that competes with the ¢rst substrate (PRPP) for
the open active site of the enzyme [28]. Four compounds
were found to be competitive against both PRPP and Hx.
This observation doesn’t seem to be accommodated by a
simple kinetic model given the predicted binding modes
from DOCK, and it is not yet clear whether the results for
these compounds re£ect an ambiguity in the assay, or a
true difference in the inhibitory or kinetic mechanism for
the trypanosomal HPRT.
The three compounds that do not show competitive inhi-
bition against PRPP are compound 3, which was uncom-
petitive with PRPP and competitive with Hx, and com-
pounds 37501 and 139585, which were non-competitive
with both PRPP and Hx. The kinetics for inhibition by
compound 3 are, however, consistent with the inhibitor
binding to the protein after the substrate PRPP. We note
that the T. cruzi HPRT is a dimeric enzyme, and that it is
possible that binding to one active site could modulate the
activity of the other [16]. With respect to compounds
37501 and 139585, closely related compounds 5062 and
139586 (differing in their lack of two chlorine atoms)
were both competitive with the substrate PRPP. We do
not yet have a rationalization for the behavior of these
inhibitor pairs.
Inhibition of trypanosomes in cell culture
Before pursuing further characterization of each of the in-
hibitors, we carried out preliminary tests of their effect on
the growth of T. cruzi. Twelve of the 16 compounds that
inhibited the puri¢ed HPRT were assayed, initially by
measuring the growth of T. cruzi in infected mouse macro-
phage cultures in the presence of each of the compounds.
Remarkably, of the eight compounds that remained soluble
in media at 10 WM, three (1, 3 and 4) inhibited the growth
of parasites (Figure 6). Of the ¢ve other compounds,
MFCD 171313 was toxic to the macrophages, and com-
pounds 2 and MFCD 112201, 37501 and 22291 did not
inhibit parasite growth. We note that four of ¢ve of the
compounds that were ineffective in vitro possess poten-
tially biologically unstable chemical groups (peptide bonds,
an ester linkage or a reactive lactone ring).
Compound 3 was subsequently tested at 5 WM as an in-
hibitor of the growth of T. cruzi in infected human epithe-
lial cells (Figure 7). Counts of the number of amastigotes
per 50 infected cells in this experiment indicate that the
Figure 6. Inhibition of the growth of T. cruzi. Twelve of the
16 compounds listed in Table 1 were tested as inhibitors of the
growth of T. cruzi in irradiated mouse macrophages. Four were
insoluble. The eight remaining compounds were tested at a
concentration of 10 WM. A cysteine protease inhibitor [30] was
used as the positive control (Control Inhib.). Lead compounds
1 and 3 were as effective as the cysteine protease inhibitor in
inhibiting parasite growth. In the absence of inhibitors, the ¢rst
intracellular cycle of parasite replication was completed and
infected macrophage cultures were virtually destroyed by 6 days
after infection (Infect. Control). Tests were terminated after 27
days because irradiated macrophages survive for 9 30 days in
culture.
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rate of replication of parasites in cells treated with com-
pound 3 at 5 WM was more than seven-fold below that in
control cells. Further, compound 3 exhibits low toxicity to
human cells as indicated by the presence of mitotic ¢gures
in the epithelial cells after 6 days in the presence of the
inhibitor (Figure 7).
Although these results establish that the compounds have
an effect on trypanosome growth in culture, they cannot
show whether or not the effect is mediated by the inhibi-
tion of the targeted enzyme, HPRT. As a ¢rst step towards
addressing this question we asked whether increased levels
of the normal substrate for the enzyme (Hx) had an effect
on the inhibition observed. The inhibition of parasite
growth by compounds 1 and 3 at 5 WM could be partially
reversed by the addition of Hx to 300 WM in the media.
Compounds 1 and 3 were also tested at 2.5 WM versus
epimastigotes (insect stage parasites) in vitro. At these con-
centrations compound 3 killed approximately 20% of the
parasites within 3 days. Compound 1 killed 100% of the
parasites within 3 days, and its trypanocidal activity was
largely reversed (88% survival) by the addition of Hx to
300 WM in the media.
Discussion
Of 22 compounds tested in the work described here, 16
inhibited the trypanosomal HPRT with inhibition con-
stants between 0.5 and 17 WM. This remarkable ef¢ciency
of computational inhibitor discovery was likely due to the
combination of a £exible ligand docking strategy that in-
corporated a desolvation correction, and the availability of
the coordinates of the target enzyme in a well-de¢ned
closed conformation. In the absence of the £exible loop
II, the open active site of the HPRT is a shallow solvent
exposed cleft [29]; consequently the best HPRT inhibitor
previously identi¢ed directly from a DOCK screen had an
IC50 of 240 WM in a study targeting the purine pocket of
the open active site of the T. foetus HGXPRT [29]. Our
data show that the majority of the compounds identi¢ed in
our DOCK screen targeting the closed active site of the
T. cruzi HPRT are, in fact, inhibitors of the enzyme, and
we ¢nd that the inhibition mechanism is generally consis-
tent with binding to the targeted empty active site. Of the
four compounds presented in Figure 3, three are trypano-
static in vitro (compounds 1, 3 and 4), and one is notable as
a submicromolar inhibitor of the trypanosomal HPRT
(compound 2).
That these compounds, identi¢ed directly from the DOCK
screen, should prove to have activity against live trypano-
somes, and indeed, that two of them are as potent against
trypanosomes in vitro as a cysteine proteinase inhibitor [30]
presently in pre-clinical trials (James McKerrow, personal
communication), is remarkable. We note that it has been a
matter of controversy in the ¢eld whether the inhibition of
the kinetoplastid HPRT should have an effect on growth
at all [6,31,32]. In a related kinetoplastid, Leishmania dono-
vani, separate HPRT and XPRT activities resolve to two
phosphoribosyl transferase genes [32]; however, the same
does not necessarily hold for T. cruzi as there are known
differences in the activities of the purine salvage pathways
of Leishmania and T. cruzi [33]. Our results, particularly the
partial reversal of inhibition observed on addition of Hx,
support an interpretation that the effect may be mediated
by inhibition of the parasite HPRT activity. While the
exact mechanisms of the inhibitors we have identi¢ed re-
Figure 7. Human epithelial cells infected
with T. cruzi. Inhibitor or DMSO control
were added to human epithelial cell
cultures 30 h after infection with a low titer
of trypomastigotes. (A) Thirty h after
infection amastigotes are visible in the cell
in the center of the ¢eld of view.
(B) Control cells, 6 days post infection.
Two cells in this ¢eld of view are ¢lled with
differentiated trypomastigotes. (C and D)
Infected cells in the presence of 5 WM
compound 3, 6 days post-infection. The
mitotic ¢gure in (D) is indicative of the low
level of toxicity for compound 3.
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main to be determined at both the structural and physio-
logical levels, these results provide intriguing circumstan-
tial evidence to support HPRT being a suitable target for
the chemotherapeutic treatment of Chagas’ disease.
Bearing these caveats in mind, we can nevertheless con-
sider each of the compounds described here as potential
leads for drug development. Each comprises a multi-ring
system that occupies a similar molecular volume (ranging
from V300 Aî 2 to V367 Aî 2) and, if the binding mode is as
predicted computationally, each occupies a similar space in
the target active site. Although the compounds are rela-
tively hydrophobic, we note that the HPRT binding site
is not uniformly hydrophobic and that the interactions in
the predicted binding modes span the different functional
regions of the site. Each of the compounds violates one
(although only one) of Lipinski’s ‘rule of ¢ve’ [34], a
widely used indicator of poor absorption and permeation
properties that provides a criterion for suitability as a drug.
Thus, compound 1 has more than 10 H-bond acceptors
(expressed as the sum of Ns and Os, 11 in this case),
and compounds 2, 3 and 4 have C log P values of 6.1, 6.5
and 6.8, respectively (all above the cutoff level of 5). To
develop these compounds as speci¢c inhibitors of the en-
zyme, several questions, of course, remain to be addressed.
Although the DOCK calculations were carried out without
consideration of the structural differences between the
T. cruzi and human enzymes, it seems clear, given the
predicted binding modes of the compounds, that there is
ample space within the HPRT active site to elaborate func-
tional groups that can exploit differences that do exist. A
differential docking strategy has been used, for example, to
identify selective inhibitors of DHFR [35], and our pre-
liminary results suggest that the compounds already exhib-
it some selectivity for the trypanosomal enzyme relative to
the human enzyme (data not shown). Second, we need
structural con¢rmation of the binding modes of these com-
pounds. Efforts are currently underway to determine crys-
tal structures of the complexes of these compounds with
the trypanosomal HPRT. Such structures should reveal the
precise binding interactions between the compounds and
the enzyme and should guide chemical modi¢cations that
improve binding speci¢city and pharmacological properties.
Knowledge of the positions of bound solute molecules will
allow improvement of the docking calculations (by specify-
ing which waters, for example, are always present) and
suggest directions in which to add functionality to increase
af¢nity and speci¢city of lead inhibitors.
At this stage, however, we can state that we have identi¢ed
a number of chemically unrelated inhibitors of the trypa-
nosomal HPRT that inhibit the growth of T. cruzi. The
purine auxotrophy of these protozoans remains a valid tar-
get for drug discovery, and whether the target proves to be
one enzyme or several, our development of inhibitors for
the HPRT is at least the ¢rst step, as the structure and
chemistry of these families of enzymes are likely to be
related; by exploiting the closed active site of the target
our inhibitors in principle will exploit a common structural
phenomenon. There are a large number of additional com-
pounds in our DOCK screens that also have favorable en-
ergy scores but have not yet been biochemically character-
ized. Given the high hit rate of the compounds tested to
date (16 of 22 yield Kis below 20 WM, and three of eight
are trypanostatic) there are, therefore, likely to be many
more potent inhibitors to be found among the compounds
that scored well in the initial DOCK run. The closed ac-
tive site structure of the trypanosomal HPRT has the po-
tential to provide a productive system for the target-based
development of inhibitory compounds that may lead to
chemotherapy of disease caused by parasites.
Signi¢cance
We have identi¢ed a number of novel inhibitors of the
HPRT by using a computational approach to target the
closed active site structure of the trypanosomal enzyme.
The DOCK screen was remarkably ef¢cient, as 16 of 22
top scoring compounds were low micro-molar inhibitors of
the target enzyme, and three of these compounds inhibited
growth of trypanosomes in culture. The results of these
preliminary studies suggest that the closed active site
structure of the HPRT from T. cruzi provides an excellent
target for inhibitor discovery. Furthermore, the trypano-
static activity of three of the inhibitors identi¢ed here pro-
vides support for the continuation of studies targeting in-




The name and commercial source of each compound that was pur-
chased for testing is listed here with the MFCD identi¢cation number,
provided by MDL Information Systems: 1159 (2,4,7-trinitro-9-£uorenyl-
idenemalononitrile from ACROS, compound 1 in the text); 5062 (£uor-
escein diacetate, ACROS); 22291 (ethyl 6-bromo-dihydro-dioxo-4-meth-
yl-7H-dibenzo(F,IJ)isoquinoline-1-carboxylate, Aldrich); 32937 (2,5-
dinitro-9-(4-methoxyphenylimino)£uorene, Aldrich); 32980 (6-(2,2-di-
chloroacetamido)chrysene, Aldrich, compound 2 in the text); 36189 (eo-
sin Y, ACROS); 37501 (2P,7P-dichloro£uorescein diacetate, ACROS);
93980 (2,7-dinitro-9-phenylcarbazole, Aldrich); 100793 (Maybridge);
102498 (Maybridge); 108271 (Maybridge); 112201 (Maybridge);
116399 (Maybridge); 124181 (Maybridge); 139585 (6-phenylimida-
zo[2,1-B] thiazole-5-carboxaldehyde-o-(2,6-dichlorobenzyl)oxime, Bio-
net); 139586 (6-phenylimidazo[2,1-B]thiazole-5-carboxaldehyde-o-(4-ni-
trobenzyl)oxime, Bionet); 141428 (3-(2-£uorophenyl)-5-(phenoxy)-1,2,4-
triazolo(4,3-C)-quinazoline, Bionet); 141430 (3-(2-£uorophenyl)-5-(2,4-
dichlorophenoxy)-1,2,4-triazolo(4,3-C)-quinazoline, Bionet, compound 3
in the text); 156385 (3,5-diphenyl-4P-methyl-2-nitrobiphenyl, Aldrich,
compound 4 in the text); 170659 (Menai); 171313 (Aldrich); 189063
(Aldrich). When not speci¢cally identi¢ed, MFCD numbers are used in
the text.
Compounds were dissolved to 10 mM in dimethyl sulfoxide (DMSO) and
stored at 4³C prior to use in inhibition assays. The purity of three of the
lead compounds reported here (2, 3 and 4) was con¢rmed by reverse
phase high performance liquid chromatography. Compound 1 is light
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sensitive and was found to degrade after several hours; this compound
was used immediately upon making up the 10 mM solution.
Computational screening
The structure of the closed ternary substrate complex of the HPRT from
T. cruzi (PDB ID: 1TC2) [18] was used to generate the target docking
surface, after all active site ligands (PRPP, HPP, water and magnesium
ions) were removed. Both monomers of the dimer were included during
the calculations because one side of the targeted closed active site is
de¢ned by atoms of the other monomer. The molecular surface was
generated using mass spectroscopy [36], and the binding site shape
described in terms of 55 sphere centers generated using SPHGEN
[23,37]. A maximum sphere radius of 4.5 Aî , and a minimum radius of
1.4 Aî , was used. The active site cluster positions were labeled as hydro-
gen bond donors and acceptors for chemical matching [38]. The DIS-
TMAP grid was generated with default parameters over a 28.5U
29.7U31.6 Aî box that extended well beyond the closed active site,
and the force ¢eld scoring grid was generated by CHEMGRID [22] using
default AMBER [39] parameters on a 0.3 Aî grid with polar and nonpolar
close cutoff limits of 2.3 and 2.8 Aî , respectively. For calculations target-
ing the open active site, the open ternary substrate complex of the
second monomer in 1TC2 was used. The binding site shape was de-
scribed in terms of 58 sphere centers; other parameters were essentially
as above.
Compounds were screened against the target site using a modi¢ed
version of the program DOCK 3.5 [19^22]. The database used was
conformationally expanded from the Available Chemicals Directory
(the ACD from MDL Information Systems, San Leandro, CA, USA) so
that up to 500 conformations for each structure in the ACD, a total of
over 34 million conformations, were evaluated [19]. Solvation correc-
tions were precalculated for each ligand and were included in the ex-
panded database ¢le [19,20]. Each ligand was matched to the target
constellation of sphere atoms and screened for steric ¢t using the DIS-
TMAP grid [40]. The DOCK bin sizes were 0.1 and 0.5 Aî for ligand and
receptor, respectively. Allowance was made in the initial ¢t for a single
overlap with protein atoms. All orientations passing this criterion were
then subjected to 10 cycles of minimization [41], and ligand interaction
energy scores evaluated using the van der Waals and electrostatic
potential distributions from CHEMGRID [22] and DELPHI [42]. Scoring
included the correction for ligand desolvation [20]. The docking calcu-
lations required 10 days on a Digital Alpha 433au workstation.
High scoring compounds in the DOCK calculation were evaluated visu-
ally with respect to the active site structure using MIDAS-Plus [43] and
O [44]. Nonpolar compounds were rejected from consideration, as were
compounds with limited interaction with the binding site. Volumes were
calculated using VOIDOO [45].
Enzyme kinetics
The HPRT from T. cruzi was puri¢ed from an overexpression system
described previously [46]. Protein concentration was determined by
Bradford assay using IgG as the standard. A continuous spectrophoto-
metric assay [26] was used for HPRT activity studies and the determi-
nation of inhibition constants (see Table 1). Enzyme was pre-equilibrat-
ed with PRPP and inhibitor at 37³C for 930 s, and reactions were
initiated by the addition of purine substrate. Production of IMP was
monitored continuously by the change in absorbance at V= 245 nm.
The concentration of the enzyme in the reaction, 34.5 nM, was well
below the concentrations of all other reactants.
For inhibition studies the concentration of either Hx (KM = 8.6 WM) or
PRPP (KM = 32.4 WM) was held constant while the other substrate was
varied. The concentration of Hx as the ¢xed substrate was 60 WM, while
PRPP was varied between 13 and 215 WM. Alternatively, the concen-
tration of PRPP was ¢xed at 67 WM, while Hx was varied between 6.25
and 100 WM. Initial velocity kinetics data were obtained for inhibitor
concentrations between 625 nM and 20 WM. Inhibition was classi¢ed
as competitive, noncompetitive or uncompetitive based on Line-
weaver^Burke plots. Where appropriate, inhibition data were modeled
as dead end inhibition of a sequential bi^bi system which, in the Line-









(where KR is a ratio of kinetic constants, and Ki is the inhibition con-
stant) [28]. For the determination of Kis, the apparent KM and Vmax at
each inhibitor concentration were determined by non-linear regression
assuming Michaelis^Menten kinetics. These values (KM/Vmax) were re-
plotted against inhibitor concentration, and the Ki taken as the negative
of the x-intercept of the least squares ¢t line [28]. Calculations were
carried out using the program `Enzyme Kinetics' from Exeter Software
(Setauket, NY, USA).
Inhibition of parasite growth in culture
For cultivation and preparation of T. cruzi, a cloned population was
derived from the Y strain [47]. This strain was cryopreserved in liquid
nitrogen and axenically cultured epimastigotes were maintained in ex-
ponential growth phase by weekly passage in brain^heart infusion tryp-
tose medium (BHT media) [48], supplemented with 20 Wg/ml hemin and
10% (v/v) heat inactivated fetal bovine serum. Host cell lines (e.g. J774
mouse macrophage, IEC-6, BESM) were cultured in RPMI-1640 supple-
mented with 5% fetal calf serum at 37³C in a humidi¢ed atmosphere
containing 5% CO2. Trypomastigotes liberated from host cells were
used to reinfect new cultures for serial maintenance of the parasites.
The protocols used for the in vitro assays of HPRT inhibitors were
essentially as described [30]. Ten mM stock solutions of test com-
pounds in DMSO were diluted with culture media and assayed at 5 or
10 WM. Culture media (with or without added inhibitor) was replaced
three times per week to insure stable culture conditions and inhibitor
levels. The effect of inhibitors on the intracellular amastigote stage was
estimated by the lag time in the release of trypomastigotes in treated
versus untreated cultures [49]. For experiments conducted at high in-
fectivity in mouse macrophages the cells were irradiated (2400 rad) prior
to infection in order to arrest their cell cycle.
Reversal of inhibition studies were carried out in triplicate. Six h after
infection, inhibitor and Hx were added, and then every 24 h replaced
with fresh media containing inhibitor and Hx. Cells were ¢xed and Giem-
sa stained 3 days after infection, and the total number of amastigotes
per 100 infected macrophages counted. For assays of activity against
epimastigotes, exponential phase epimastigotes were transferred to 25
cm2 cell culture £asks containing 5 ml BHT media at a ¢nal concentra-
tion of 106 parasites/ml. Inhibitor and Hx were added at a ¢nal concen-
tration of 2.5 and 300 WM, respectively, and after 3 days epimastigote
survival was estimated by counting in a hemocytometer.
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